Latest Headlines

Latest Headlines

Galapagos hits all-time high as 24-week RA data shorten odds of AbbVie deal

Galapagos has presented a surprise-free update on the trial of its AbbVie-partnered rheumatoid arthritis drug, filgotinib. The data led observers to cut the odds of AbbVie of taking up its $200 million (€182 million) buy-in option--or even making a bid to acquire Galapagos outright--and led to the company's stock hitting an all-time high on Euronext Amsterdam.

Cortendo outlines plan to up sticks to Ireland to snag tax benefits

​After a hectic period in which every biopharma seemed to be seeking to relocate its way to a lower tax rate, the furor over who pays what and where has died down a little in recent months. But the number crunchers are still working away in the background--and in the case of Cortendo they are on the cusp of engineering a move to Ireland.

Shares in Bavarian Nordic dip after short seller posts broadside against its cancer vaccine

Hedge fund Kerrisdale Capital has orchestrated an attack on Bavarian Nordic, the centerpiece of which is a 52-page report that argues the valuation of the Danish drugmaker is based on misplaced faith in the likelihood of its cancer vaccine succeeding in Phase III.

Emergent launches in-licensed military-grade autoinjector outside the U.S., aims for FDA approval

Emergent BioSolutions has launched a military-grade intramuscular autoinjector device for self-administered antidotes or other chemical threat treatments. For now, the rollout is only ex-U.S., but the infectious disease specialist said it will seek FDA approval for the device, dubbed Emergard.

Generics maker Amneal revamping former J&J plant in Ireland

U.S.-based generics drugmaker Amneal Pharmaceuticals will recycle a plant in Ireland that Johnson & Johnson abandoned some years ago, with plans to have about 300 workers when it reopens in a few years. The move comes as the 15-year-old company works its way up the ladder of generics makers.

Amid ongoing restructuring and layoffs at Siemens, healthcare leads

Healthcare was one of the strongest segments at German conglomerate Siemens last quarter, both in terms of sales growth and profitability. That could help insulate this business, comprised mostly of imaging and diagnostics, from an ongoing restructuring that aims to trim employees and costs from its worst performing businesses.

AZ, GSK ink academic hookup; EU blasts past 2014 fundraising haul; Erytech plans U.S. IPO

In this week's EuroBiotech Report, data from market analyst Biocom shows that biotechs traded in Europe raised €3 billion ($3.3 billion) in the first half of the year, more than they gathered in all of 2014. AC Immune and Erytech could contribute to the back half of 2015 being an equally busy period. And more.

AstraZeneca, GSK snag a direct line to researchers at Cambridge academic hub

AstraZeneca and GlaxoSmithKline have secured direct connections to researchers at the University of Cambridge and its associated academic institutions. The arrangement is part of a "matchmaking" scheme, in which drugmakers will provide academics with funding for collaborative research and access to their experimental therapies.

Startup raises $35M to back first FDA-approved dermal filler for acne scars

Innovations in aesthetic medicine have proven lucrative in the medical device industry, given a growing and aging population with disposable income. Investors are betting that a dermal filler to treat acne scars--that's the first approved by the FDA--could be the next ticket to successful commercialization in aesthetics.

Erytech pushes ahead with plan to file IPO on Nasdaq to fund cancer pipeline

Erytech is poised to become the latest in a long line of European biotechs to head to Wall Street in search of cash. The proposal marks an escalation of the cancer biotech's long-running flirtation with U.S. investors, which has already seen it set up on the OTC market and tap stateside sources for its previous fundraising round.